HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2028
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Human epidermal growth factor receptor type 2 (HER2)-negative breast cancer is one of the most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can generally be subdivided into two major groups: HER2-, estrogen receptor (ER)+ and/or progesterone receptor (PR)+ and HER2-, ER-, and PR- (triple-negative breast cancer, or TNBC). Historically HR+ breast cancer has typically been treated with hormone therapies which is the cornerstone of treatment for patients with this disease while physicians have typically relied on chemotherapy for patients with triple negative breast cancer. This has significantly changed in the last 5 years.
GlobalData is expecting a total of 9 new entrants to launch over the forecast period in the 8MM from 2018–2028 while specific marketed agents are expected to move into earlier lines of treatment. The competition will be particularly fierce in HER2-/HR+ breast cancer, with CDK4/6, PI3K/AKT, and HDAC inhibitors competing for market share with endocrine-based therapies in later lines of treatment. In TNBC, checkpoint inhibitors, PARP inhibitors and antibody drug conjugates will compete in specific patient segments, and are expected to ultimately lower the unmet needs in this patient population.
KEY QUESTIONS ANSWERED
Nine late-stage pipeline agents are going to enter the HER2-negative breast cancer market from 2018 onwards. Will the impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
What are the current unmet needs in HER2-negative breast cancer, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
What is the market outlook in the 8MM from 2018-2028? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
What are the main corporate trends? Who are the current and future players?
Scope
Overview of HER2-negative breast cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline HER2-negative breast cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting HER2-negative breast cancer therapeutics sales in the 8MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
Analysis of the current and future market competition in the global HER2-negative breast cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
The main drivers of growth include the anticipated approval and launch of 9 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.
Among the late-stage pipeline products and marketed agents, CDK4/6 inhibitors, checkpoint inhibitors and PI3K/AKT inhibitors are expected to generate the greatest revenues over the forecast period.
The most important unmet needs in the HER2-negative market include: Personalized therapies in TNBC, agents to tackle endocrine resistance and improved convenience for administration of hormone therapies.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global HER2-negative breast cancer therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2-negative breast cancer market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global HER2-negative breast cancer therapeutics market from 2018-2028.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Roche
Astrazeneca
Novartis
Eli Lilly
Merck
Eisai
Celgene
Chipscreen biosciences
OBI Pharma
PolyPhor
Syndax
Radius Health
Immunomedics
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.